OBJECTIVE: Nigrostriatal reserve refers to the threshold of neuronal injury to dopaminergic cell bodies and their terminal fields required to produce parkinsonian motor deficits. Inferential studies have estimated striatal dopamine reserve to be at least 70%. Knowledge of this threshold is critical for planning interventions to prevent symptom onset or reverse nigrostriatal injury sufficient to restore function in people with Parkinson disease. In this study, we determine the nigrostriatal reserve in a non-human primate model that mimics the motor manifestations of Parkinson disease. METHODS: Fifteen macaque monkeys received unilateral randomized doses of the selective dopaminergic neuronal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. We compared blinded validated ratings of parkinsonism to in vitro measures of striatal dopamine and unbiased stereologic counts of nigral neurons after tyrosine hydroxylase immunostaining. RESULTS: The percent of residual cell counts in lesioned nigra correlated linearly with the parkinsonism score at 2 months (r=-0.87, p<0.0001). The parkinsonism score at 2 months correlated linearly with the percent residual striatal dopamine (r=-0.77, p=0.016) followed by a flooring effect once nigral cell loss exceeded 50%. A reduction of about 14 to 23% of nigral neuron counts or 14% to 37% of striatal dopamine was sufficient to induce mild parkinsonism. CONCLUSIONS: The nigral cell body and terminal field injury needed to produce parkinsonian motor manifestations may be much less than previously thought.
OBJECTIVE: Nigrostriatal reserve refers to the threshold of neuronal injury to dopaminergic cell bodies and their terminal fields required to produce parkinsonian motor deficits. Inferential studies have estimated striatal dopamine reserve to be at least 70%. Knowledge of this threshold is critical for planning interventions to prevent symptom onset or reverse nigrostriatal injury sufficient to restore function in people with Parkinson disease. In this study, we determine the nigrostriatal reserve in a non-human primate model that mimics the motor manifestations of Parkinson disease. METHODS: Fifteen macaque monkeys received unilateral randomized doses of the selective dopaminergic neuronal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. We compared blinded validated ratings of parkinsonism to in vitro measures of striatal dopamine and unbiased stereologic counts of nigral neurons after tyrosine hydroxylase immunostaining. RESULTS: The percent of residual cell counts in lesioned nigra correlated linearly with the parkinsonism score at 2 months (r=-0.87, p<0.0001). The parkinsonism score at 2 months correlated linearly with the percent residual striatal dopamine (r=-0.77, p=0.016) followed by a flooring effect once nigral cell loss exceeded 50%. A reduction of about 14 to 23% of nigral neuron counts or 14% to 37% of striatal dopamine was sufficient to induce mild parkinsonism. CONCLUSIONS: The nigral cell body and terminal field injury needed to produce parkinsonian motor manifestations may be much less than previously thought.
Authors: R E Yee; I Irwin; C Milonas; D B Stout; S C Huang; K Shoghi-Jadid; N Satyamurthy; L E Delanney; D M Togasaki; K F Farahani; K Delfani; A M Janson; M E Phelps; J W Langston; J R Barrio Journal: Mov Disord Date: 2001-09 Impact factor: 10.338
Authors: C S Lee; A Samii; V Sossi; T J Ruth; M Schulzer; J E Holden; J Wudel; P K Pal; R de la Fuente-Fernandez; D B Calne; A J Stoessl Journal: Ann Neurol Date: 2000-04 Impact factor: 10.422
Authors: G Webster Ross; Helen Petrovitch; Robert D Abbott; James Nelson; William Markesbery; Daron Davis; John Hardman; Lenore Launer; Kamal Masaki; Caroline M Tanner; Lon R White Journal: Ann Neurol Date: 2004-10 Impact factor: 10.422
Authors: LinLin Tian; Morvarid Karimi; Susan K Loftin; Chris A Brown; HuChuan Xia; JinBin Xu; Robert H Mach; Joel S Perlmutter Journal: PLoS One Date: 2012-02-16 Impact factor: 3.240
Authors: Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu Journal: Ageing Res Rev Date: 2019-11-22 Impact factor: 10.895
Authors: Laura L Dugan; LinLin Tian; Kevin L Quick; Josh I Hardt; Morvarid Karimi; Chris Brown; Susan Loftin; Hugh Flores; Stephen M Moerlein; John Polich; Samer D Tabbal; Jonathan W Mink; Joel S Perlmutter Journal: Ann Neurol Date: 2014-07-22 Impact factor: 10.422
Authors: Morvarid Karimi; LinLin Tian; Christopher A Brown; Hubert P Flores; Susan K Loftin; Tom O Videen; Stephen M Moerlein; Joel S Perlmutter Journal: Ann Neurol Date: 2013-02-19 Impact factor: 10.422
Authors: Michael F Salvatore; Jennifer Terrebonne; Victoria Fields; Danielle Nodurft; Cori Runfalo; Brian Latimer; Donald K Ingram Journal: Neurobiol Aging Date: 2015-10-19 Impact factor: 4.673
Authors: Christopher A Brown; Morvarid K Karimi; LinLin Tian; Hugh Flores; Yi Su; Samer D Tabbal; Susan K Loftin; Stephen M Moerlein; Joel S Perlmutter Journal: Ann Neurol Date: 2013-09-16 Impact factor: 10.422